An in vivo model for investigating alpha 1- and alpha 2-receptors in the CNS: studies with mianserin.
Locomotor activity in rats was reduced by intracisternal (i.cis.) injection of the selective alpha 2-agonist clonidine and increased by the i.cis. administration of the selective alpha 1-agonists phenylephrine and methoxamine. These responses to i.cis. administered clonidine, phenylephrine and methoxamine were examined in rats pretreated subcutaneously (s.c.) with various alpha-adrenoceptor antagonists believed to exhibit preference for alpha 2- or alpha 1-receptors in peripheral tissues. At a dose that eliminated the locomotor depressant effect of clonidine, the alpha 2 -antagonist yohimbine did not antagonize the locomotor stimulant effects of phenylephrine and methoxamine. Similar results were obtained in animals pretreated with another alpha 2-antagonist piperoxane. The alpha 1-antagonist prazosin abolished the increase in motor activity elicited by phenylephrine and methoxamine, but at the same dose prazosin did not offset the decrease in motor activity caused by clonidine. The alpha 1-antagonist azapetine, at a dose that inhibited the increase in motor activity elicited by phenylephrine, was without effect on the decrease in activity produced by clonidine. These findings indicate that the locomotor responses to the alpha 2-agonist clonidine and the alpha 1-agonist phenylephrine (or methoxamine) can be used for determining whether or not a particular substance acts in vivo as a selective antagonist for alpha 1- or alpha 2-receptors in the CNS. In rats pretreated s.c. with 13.5 mg/kg of mianserin, the locomotor depressant effect of clonidine and stimulant action of phenylephrine were unchanged. At 27 mg/kg s.c., mianserin antagonized the responses to both clonidine and phenylephrine. Therefore, in this in vivo model system, mianserin given systemically did not display any appreciable selectivity for blocking alpha 1- or alpha 2-receptors in the CNS.